Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk by 42% in Phase 3 Trial
Phase 3 trial results presented at ESMO 2026 show that adding personalized mRNA vaccine intismeran to pembrolizumab reduces melanoma recurrence ...
Phase 3 trial results presented at ESMO 2026 show that adding personalized mRNA vaccine intismeran to pembrolizumab reduces melanoma recurrence ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine